Literature DB >> 12595592

Endostatin and vascular endothelial cell growth factor (VEGF) in piglet lungs: effect of inhaled nitric oxide and hyperoxia.

Ikechukwu I Ekekezie1, Donald W Thibeault, Mohammad H Rezaiekhaligh, Michael Norberg, Sherry Mabry, Xiaoming Zhang, William E Truog.   

Abstract

Pulmonary hyperoxic injury manifests as widespread alveolar-epithelial and microvascular endothelial cell necrosis, resolution of which requires angiogenesis. We investigated the hypothesis that inhaled nitric oxide (iNO) and hyperoxia each decreases lung vascular endothelial growth factor (VEGF) expression but increases endostatin and that concurrent administration of both gases will show a greater effect. Piglets were randomized to breathe for 5 d room air (RA); RA + NO (RA + 50 ppm NO), O(2) (hyperoxia, F(I)O(2) >0.96), O(2) + NO, or O(2) + NO + REC (O(2) + NO plus recovery in 50% O(2) for 72 h. After the piglets were killed, we measured lung capillary leak, VEGF mRNA, VEGF, and endostatin protein in homogenates, plasma, and lavage. VEGF mRNA decreased significantly with O(2) and O(2) + NO compared with breathing RA (p < or = 0.05). VEGF protein declined in the experimental groups with a significant reduction in the recovery group compared with the RA group (p < or = 0.05). Similar but more dramatic, endostatin declined in all groups relative to the RA group (p < 0.001). Lavage fluid VEGF protein and lung capillary leak rose significantly with O(2) and O(2) + NO compared with RA, but endostatin was unchanged. At 72 h of recovery from hyperoxia, VEGF mRNA and lavage fluid VEGF but not lung VEGF protein had normalized. Hyperoxia and iNO suppresses lung endostatin expression, but iNO unlike hyperoxia alone does not alter lung VEGF production. Hyperoxia paradoxically raises lavageable VEGF levels. This latter effect and that on VEGF mRNA level but not protein is abrogated by recovery in reduced F(I)O(2) for 72 h.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595592     DOI: 10.1203/01.PDR.0000050121.70693.1A

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses.

Authors:  Alicia K Olivier; Jack M Gallup; Albert van Geelen; Mark R Ackermann
Journal:  Exp Lung Res       Date:  2011-02-11       Impact factor: 2.459

Review 2.  Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns.

Authors:  Said A Omar; Amal Abdul-Hafez; Sherif Ibrahim; Natasha Pillai; Mohammed Abdulmageed; Ranga Prasanth Thiruvenkataramani; Tarek Mohamed; Burra V Madhukar; Bruce D Uhal
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

3.  Hyperoxia enhances VEGF release from A549 cells via post-transcriptional processes.

Authors:  Jeffrey S Shenberger; Lianqin Zhang; Richard J Powell; Aaron Barchowsky
Journal:  Free Radic Biol Med       Date:  2007-06-06       Impact factor: 7.376

4.  Hypoxia-induced increase of endostatin in murine aorta and lung.

Authors:  Renate Paddenberg; Petra Faulhammer; Anna Goldenberg; Wolfgang Kummer
Journal:  Histochem Cell Biol       Date:  2006-02-08       Impact factor: 4.304

5.  The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival.

Authors:  Marco Mura; Bing Han; Cristiano F Andrade; Rashmi Seth; David Hwang; Thomas K Waddell; Shaf Keshavjee; Mingyao Liu
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

6.  Mechanical ventilation strategies alter cardiovascular biomarkers in an infant rat model.

Authors:  Philipp Baumann; Susanne Wiegert; Francesco Greco; Sven Wellmann; Pietro L'Abate; Vincenzo Cannizzaro
Journal:  Physiol Rep       Date:  2018-01

7.  Pathogenic CD8+ T Cells Cause Increased Levels of VEGF-A in Experimental Malaria-Associated Acute Respiratory Distress Syndrome, but Therapeutic VEGFR Inhibition Is Not Effective.

Authors:  Thao-Thy Pham; Melissa Verheijen; Leen Vandermosten; Katrien Deroost; Sofie Knoops; Kathleen Van den Eynde; Louis Boon; Chris J Janse; Ghislain Opdenakker; Philippe E Van den Steen
Journal:  Front Cell Infect Microbiol       Date:  2017-09-20       Impact factor: 5.293

8.  Plasma endostatin correlates with hypoxia and mortality in COVID-19-associated acute respiratory failure.

Authors:  Sana Asif; Thoralph Ruge; Anders Larsson; Sara Bülow Anderberg; Miklos Lipcsey; Robert Frithiof; Michael Hultström
Journal:  Biomark Med       Date:  2021-10-20       Impact factor: 2.851

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.